How Beta-1,3/1,6-Glucan Activates the Immune System

Beta-1,3/1,6-glucan is a sugar polymer found in the cell walls of baker’s yeast, certain mushrooms, and some fungi, and it has become one of the most studied natural immune modulators of the past three decades. Unlike vitamins or minerals that fill a nutritional gap, this molecule works by interacting directly with receptors on immune cells, essentially giving your innate immune system a more responsive footing without switching it into overdrive. The research behind it spans upper respiratory infections, surgical recovery, wound healing, and even experimental cancer therapy, though the strength of evidence varies widely across those applications.

What Beta-1,3/1,6-Glucan Actually Is

Beta-glucans are a broad family of polysaccharides, long chains of glucose molecules linked together. The “1,3/1,6” label describes the specific way the glucose units connect: a backbone of glucose linked at the 1,3 positions, with side branches attached at the 1,6 positions. This branching pattern matters because it determines how the molecule interacts with the immune system. Cereal grains like oats contain beta-glucans too, but those are predominantly 1,3/1,4-linked and are better known for lowering cholesterol than for immune effects. The 1,3/1,6 configuration is the one tied to immune modulation, and its primary commercial source is the cell wall of Saccharomyces cerevisiae, common baker’s or brewer’s yeast.

Not all yeast-derived beta-glucans are identical. A comparison of beta-glucan samples from different yeast strains found that purity ranged from about 74% to 86% beta-glucan content, with glycogen contamination varying from 0% to 20% and branching density ranging from roughly 2% to 9%.¹ Those differences in purity and branching aren’t academic: they affect how strongly the molecule binds to immune receptors, which partly explains why clinical results can vary between branded products.

How It Activates Immune Cells

Your innate immune system evolved to recognize common structural features of pathogens, and the beta-1,3/1,6 branching pattern is one of them. Fungi use this molecule as a structural component of their cell walls, so immune cells treat it as a signal that something fungal is present. The primary receptor for this recognition is Dectin-1, a receptor on the surface of macrophages, dendritic cells, and other immune cells that specifically binds beta-1,3/1,6-glucan.² When Dectin-1 grabs onto the glucan, it clusters together and triggers an internal signaling cascade that puts the immune cell on alert.

A second receptor plays a complementary role. Complement receptor 3 (CR3) sits on neutrophils and natural killer cells. Soluble beta-glucan binds to a lectin site on CR3 and primes it so that when the cell encounters a target already tagged by the complement system (marked with a fragment called iC3b), the primed cell can kill that target more effectively than it otherwise would.³ This CR3 priming is particularly relevant to the cancer research discussed later, because tumor cells tagged by therapeutic antibodies can also be coated with complement fragments.

The practical upshot is that beta-1,3/1,6-glucan does not directly kill anything. It puts certain immune cells in a heightened state of readiness, so when they encounter something that needs dealing with, they respond faster and more forcefully.

Trained Immunity: A Longer-Lasting Effect

One of the more interesting findings in recent immunology is that beta-glucan doesn’t just cause a temporary spike in immune alertness. It can reprogram innate immune cells so they remain more responsive for weeks or months, a phenomenon researchers call “trained immunity.” This is surprising because the innate immune system was long thought to lack memory; that was supposed to be the job of antibodies and T cells in the adaptive branch. Beta-glucan helped upend that assumption.

The reprogramming works through changes to how genes in macrophages and monocytes are packaged and read. Beta-glucan exposure triggers epigenetic modifications, essentially chemical marks on the DNA-packaging proteins that keep certain immune-response genes in a more accessible, ready-to-activate state.⁴ The cells also undergo a metabolic shift, switching their energy production toward pathways that support rapid inflammatory responses when needed. This metabolic reprogramming depends on the cell’s antioxidant machinery, particularly the production of glutathione, which supports the epigenetic changes that sustain the trained state.⁵

An important nuance: trained immunity doesn’t mean your immune system is constantly inflamed. In broiler chickens fed beta-glucan without any infection challenge, researchers found that the glucan altered cytokine profiles but did not produce strong immune activation in the absence of a real threat.⁶ The trained cells are primed, not firing. They respond more vigorously when a genuine pathogen arrives, but they don’t stay perpetually switched on. This distinction is part of why beta-glucan has a relatively clean safety profile.

Upper Respiratory Infections and Exercise Recovery

The most studied human application of oral beta-1,3/1,6-glucan is its effect on upper respiratory tract infections, especially in people under physical stress. Marathon runners, for instance, are known to have a temporary dip in immune function after a race, making them more susceptible to colds and similar infections in the following weeks. A study of marathon athletes found that those taking either 250 mg or 500 mg of beta-glucan daily for four weeks reported significantly fewer upper respiratory symptoms, better overall health, and improvements in mood compared to a placebo group.⁷

A separate double-blind trial in marathon runners compared soluble and insoluble forms of yeast beta-glucan against placebo. The insoluble form reduced the number of symptomatic days from respiratory infections, while the soluble form did not show the same benefit.⁸ That finding underscores the structural point: even within yeast beta-glucans, the physical form and particle size influence the outcome. Insoluble, particulate beta-glucan appears to engage Dectin-1 more effectively than soluble fragments do.

The evidence extends beyond athletes. In a trial of older adults, those taking daily yeast beta-1,3/1,6-glucan had 17 confirmed upper respiratory infections compared to 28 in the placebo group, and the duration of symptoms trended shorter, though the difference didn’t reach conventional statistical significance.⁹ Older adults are an interesting population for this research because their innate immune responses naturally weaken with age, so a compound that restores some of that responsiveness has clear potential value. The results are promising but not yet decisive; larger trials in this group would help clarify how meaningful the benefit really is.

Surgical Patients and Hospital Infections

Some of the earliest and most striking clinical data on beta-1,3/1,6-glucan came from surgical settings, where the compound was given intravenously rather than orally. In a Phase I/II trial of high-risk surgical patients, those receiving PGG-glucan (a purified, injectable form) had significantly fewer infectious complications per infected patient, required far fewer days of intravenous antibiotics, and spent less time in intensive care.¹⁰

A larger follow-up trial looked specifically at patients undergoing high-risk gastrointestinal surgery. Among those having noncolorectal procedures, PGG-glucan reduced serious infections and death by about 39% compared to placebo. In the subgroup of malnourished patients having noncolorectal surgery, the benefit was even more pronounced.¹¹ These are some of the hardest clinical endpoints available, actual infection rates and mortality, rather than surrogate markers. The catch is that the intravenous form used in these trials is a pharmaceutical-grade product, not the same thing as the oral supplements sold in health stores. Oral and intravenous delivery engage the immune system through somewhat different pathways.

How Oral Beta-Glucan Gets Past the Gut

A reasonable question: if beta-1,3/1,6-glucan is a large, insoluble polysaccharide, how does swallowing it lead to systemic immune effects? It doesn’t cross the gut lining the way small molecules do. Instead, it relies on specialized uptake cells in the gut-associated lymphoid tissue. Peyer’s patches, clusters of immune tissue in the small intestine, contain M cells whose job is to sample particles from the gut lumen and shuttle them to immune cells waiting underneath. Beta-glucan particles get taken up by these M cells and delivered to macrophages and dendritic cells in the Peyer’s patches.¹²

Recent research has confirmed that the Dectin-1 receptor is involved in this absorption process as well, mediating the uptake of beta-glucan by immune cells within the Peyer’s patches and facilitating transport through the lymphatic system.¹³ Once inside macrophages, larger beta-glucan particles are gradually broken down into smaller fragments that can then travel through the bloodstream and prime immune cells elsewhere in the body. This explains the delay often seen in oral beta-glucan studies: the effects build over days to weeks as the compound is processed and distributed.

Experimental Cancer Research

Beta-1,3/1,6-glucan has attracted attention in oncology research, not as a standalone cancer treatment but as a potential booster for existing antibody therapies. The logic ties back to the CR3 priming mechanism. Therapeutic monoclonal antibodies used in cancer treatment can flag tumor cells for destruction by the complement system. Beta-glucan, by priming the CR3 receptor on neutrophils and natural killer cells, could make those immune cells more effective at killing the antibody-tagged tumor cells. In animal models, the combination of beta-glucan with antitumor monoclonal antibodies has shown significant tumor regression and improved survival across several tumor types.¹⁴ This effect has been demonstrated against human non-small-cell lung carcinoma grafts in mice.¹⁵

A Phase II human trial tested an injectable form of beta-1,3/1,6-glucan (called Imprime PGG or BTH1677) alongside cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. By the investigators’ assessment, the group receiving beta-glucan had a tumor response rate of about 48%, compared to about 23% in the control group.¹⁶ The central review, which tends to be more conservative, showed a smaller difference that wasn’t statistically significant. The results were encouraging enough to warrant further study, but this remains firmly in the experimental stage.

A separate animal study explored a different angle: whether oral beta-glucan could counteract the immune suppression caused by chemotherapy itself. Mice treated with gemcitabine, a chemotherapy drug that causes severe drops in blood cell counts, showed recovery of blood cell production and restored natural killer cell activity when given oral yeast beta-glucan alongside the drug.¹⁷ More recently, researchers have begun investigating whether beta-glucan-induced trained immunity could enhance the response to cancer vaccines by reprogramming macrophages that normally suppress immune activity within tumors.¹⁸ All of this is preclinical or early-phase human research. No health authority has approved beta-glucan as a cancer therapy.

Wound Healing and Skin Repair

Applied topically, beta-1,3/1,6-glucan speeds wound healing through a different aspect of its macrophage-activating ability. When macrophages in a wound bed are activated by beta-glucan, they stimulate collagen deposition, the formation of new blood vessels, and the regrowth of the outer skin layer.¹⁹ This has led to beta-glucan being incorporated into a growing number of wound dressings, serums, and post-procedure skincare products.

The most compelling recent wound data comes from diabetic models. Diabetic wounds are notoriously slow to heal because chronic inflammation stalls the normal repair process. In diabetic mice, a beta-glucan hydrogel applied daily achieved roughly 91% wound closure by day 14, compared to about 66% in untreated controls. The glucan shifted macrophages in the wound toward a repair-promoting state and reduced the expression of inflammatory signals while boosting anti-inflammatory ones.²⁰ If these findings translate to humans, beta-glucan dressings could be useful for managing diabetic ulcers, one of the more stubborn clinical problems in wound care.

Safety and What the Doses Look Like

A review of multiple studies concluded that oral intake of insoluble yeast beta-1,3/1,6-glucan is safe and has immune-strengthening effects.²¹ Most human trials of oral beta-glucan have used daily doses between 250 mg and 500 mg, though there is no universally agreed-upon dose and the optimal amount likely depends on the product’s purity and particle characteristics.

For the injectable pharmaceutical form (BTH1677), Phase I dose-escalation studies in healthy volunteers found no serious adverse events at single doses up to 6 mg/kg or repeated daily doses up to 4 mg/kg. The most common side effects were mild to moderate and included flushing, headache, nausea, and rash.²² These are IV-specific effects and shouldn’t be extrapolated to oral supplements, which bypass the blood-contact issues that cause flushing and rash with direct infusion.

A concern that sometimes comes up is whether stimulating the innate immune system could worsen autoimmune conditions. In mouse models of psoriasis and psoriatic arthritis, beta-glucan variants did not trigger or worsen the disease. In fact, they reduced the autoimmune inflammation, an effect mediated partly through activation of a particular receptor (CD206) on macrophages that promotes resolution of inflammation rather than amplification of it.²³ This is a single study in mice and shouldn’t be taken as license for anyone with autoimmune disease to self-treat, but it does push back against the assumption that immune stimulation necessarily means autoimmune risk.

Agricultural and Veterinary Uses

Beta-1,3/1,6-glucan has found a significant market outside human health. Since the European Union restricted antibiotic growth promoters in animal feed, producers have been searching for alternatives that improve animal health without contributing to antibiotic resistance. Yeast cell wall products containing beta-glucan are now widely used in poultry and aquaculture. In broiler chickens, supplementation with yeast cell wall extract containing beta-glucan and mannan oligosaccharides improved body weight gain, feed conversion, and the balance of gut bacteria, reducing pathogenic species while increasing beneficial lactobacilli.²⁴

In Nile tilapia, a major farmed fish species, dietary beta-glucan boosted antioxidant capacity, immune markers like lysozyme activity, and the ability of immune cells to engulf pathogens.²⁵ Aquaculture is an area where alternatives to antibiotics are especially needed because fish farms are breeding grounds for resistant bacteria, and any reduction in antibiotic use has outsized environmental benefits.

Beta-Glucan as a Diagnostic Tool

In a completely different context, beta-1,3-D-glucan shows up in hospital medicine not as a treatment but as a blood test. Because beta-glucan is a structural component of most fungal cell walls (except those of Cryptococcus and the Mucorales group), elevated levels in a patient’s blood can signal an invasive fungal infection. The test, commonly called the BDG assay, is used as a screening tool in immunocompromised patients, particularly those with blood cancers or those who have received organ transplants.²⁶

A meta-analysis of relevant studies found that the serum BDG assay has good overall diagnostic accuracy for distinguishing proven or probable invasive fungal infections from cases without infection.²⁷ This raises a practical footnote for anyone taking beta-glucan supplements: if you need a BDG blood test while supplementing with oral or especially injectable beta-glucan, the result could theoretically be confounded. It’s worth mentioning to your doctor, though the oral supplement doses commonly used are unlikely to dramatically spike serum levels the way an active systemic fungal infection would.